Switch Bioworks reported on Oct. 13 that its engineered microbes produced five times more nitrogen than control strains in grow-room studies — the result that now underpins a strategic collaboration with Bayer Crop Science on biological nitrogen fertilizer.

The partnership will initially focus on nitrogen fixation and Switch's genetic switch technology, a platform designed to help microbes establish on plant roots before activating nitrogen production. The companies did not disclose financial terms or a commercialization timeline.

For corn growers, the stakes are straightforward. Conventional nitrogen fertilizer represents one of the largest variable input costs per acre, and any biological product that reliably replaces a portion of synthetic nitrogen would move the needle on margins. Whether Switch's platform can do that at field scale remains unproven — the fivefold result comes from controlled studies, not harvested trials.

Why root establishment has blocked biological nitrogen

The technical problem Switch set out to solve is well known in the biologicals segment. Microbes engineered to produce nitrogen often fail to establish on roots, while strains that colonize roots reliably tend not to generate enough nitrogen to meaningfully support a crop.

Switch's genetic switch separates the two functions. The engineered microbes — originally developed at Stanford University — first establish on the root, then "switch on" nitrogen production once colonization is secure. In the company's grow-room studies, this programmed delay outperformed control strains that produced nitrogen continuously.

The approach is protected by seven patent families, according to the company.

What the executives said

Tim Schnabel, founder and CEO of Switch Bioworks, framed the deal as validation of the platform.

"Bayer's commitment to advancing agriculture through innovative biological solutions is unparalleled, and they have long demonstrated a sophisticated understanding of the complexities of nitrogen performance in corn," Schnabel said. "Partnering with Bayer is a testament to the potential of our platform, and this collaboration marks a pivotal milestone for our company."

Benoit Hartmann, insights, innovation and partnerships lead at Bayer Crop Science, positioned biologicals as one tool among several for crop nutrition management.

"Growers need more options to manage unpredictable conditions, protect crop potential and optimize their crop nutrition programs," Hartmann said. "They also need to do this while meeting increasing expectations from consumers for more resilient and responsible food systems. Biologicals are another way we address these challenges."

Hartmann said Bayer pairs innovators such as Switch with its own capabilities in product development, formulation, field testing, commercialization and crop genetics.

Where the trials stand

Switch has received USDA and EPA authorization for field trials of its engineered microbial fertilizer. Trials are underway at multiple sites across the Midwest, the company said — a distinction worth holding onto: condition reports and controlled grow-room data are not harvested field results, and performance under variable soil, weather and management conditions will determine commercial viability.

The company has also secured approvals in Brazil from the National Technical Biosafety Commission, known as CTNBio, opening a second regulatory jurisdiction for trial work.

Reading the deal

For input makers, the collaboration signals that Bayer continues to build its biologicals pipeline through partnerships rather than internal development alone. For growers, the near-term practical effect is limited until field trial data replaces grow-room numbers; synthetic nitrogen budgets for the coming seasons remain unchanged.

Founded in 2022 out of Stanford University and headquartered in San Carlos, California, Switch is developing its programmable biology platform with an initial focus on the nitrogen fertilizer market. The company said the platform could extend to energy, industrial biotechnology and human-health microbiome research.

The next concrete signal for the market will be Midwest field trial results — and, eventually, disclosure of how Bayer intends to formulate and commercialize whatever survives them.